

1 Deep immune profiling reveals early-stage and highly coordinated immune 2 responses in mild COVID-19 patients

3 Christophe M. Capelle^{1,2,#}, Séverine Cire^{1,#}, Olivia Domingues¹, Isabelle Ernens³, Fanny Hedin⁴,
4 Aurélie Fischer³, Chantal Snoeck¹, Wim Ammerlaan⁵, Maria Konstantinou⁴, Kamil Grzyb⁶, Alex
5 Skupin⁶, Cara L. Carty⁷, Christiane Hilger¹, Georges Gilson⁸, Aljosa Celebic³, Antonio Del Sol⁶, Ian
6 M. Kaplan⁷, Fay Betsou^{5,9}, Tamir Abdelrahman⁹, Antonio Cosma⁴, Michel Vaillant³, Guy
7 Fagherazzi³, Markus Ollert^{1,10,§}, Feng Q. Hefeng^{1,11,§}

8
9 ¹, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), 29, rue Henri
10 Koch, L-4354, Esch-sur-Alzette, Luxembourg

11 ², Faculty of Science, Technology and Medicine, University of Luxembourg, 2, avenue de
12 Université, L-4365, Esch-sur-Alzette, Luxembourg

13 ³, Department of Population Health, Luxembourg Institute of Health, 1A-B, rue Thomas Edison, L-
14 1445, Strassen, Luxembourg

15 ⁴, National Cytometry Platform, Luxembourg Institute of Health, L-4354 Esch-sur-Alzette,
16 Luxembourg

17 ⁵, Integrated BioBank of Luxembourg (IBBL), 1, rue Louis Rech, L-3555, Dudelange, Luxembourg

18 ⁶, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Campus
19 Belval, 6, Avenue du Swing, L-4367 Belvaux, Luxembourg

20 ⁷, Adaptive Biotechnologies, 1551 Eastlake Ave E, Seattle, WA 98102, USA

21 ⁸, Centre Hospitalier de Luxembourg (CHL) 4, Rue Nicolas Ernest Barblé, L-1210, Luxembourg,
22 Luxembourg

23 ⁹, Laboratoire national de santé (LNS), 1, rue Louis Rech, L-3555, Dudelange, Luxembourg

24 ¹⁰, Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis
25 (ORCA), University of Southern Denmark, Odense, 5000 C, Denmark

26 ¹¹, Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, D-
27 45122 Essen, Germany

28 #, contributed equally as first authors. §, contributed equally as last authors. *Correspondence to:
29 Markus.Ollert@lih.lu and Feng.He@lih.lu

30
31 **Running title: coordinated early immune responses in mild COVID-19 patients**

32 Abstract

33 **While immunopathology has been widely studied in severe COVID-19 patients,**
34 **immunoprotective factors in non-hospitalized patients have remained largely elusive. We**
35 **systematically analyzed 484 peripheral immune cell signatures, various serological**
36 **parameters and TCR repertoire in a longitudinal cohort of 63 mild and 15 hospitalized**
37 **patients versus 14 asymptomatic and 26 control individuals. Within three days following**
38 **PCR diagnosis, we observed coordinated responses of CD4 and CD8 T cells, various**
39 **antigen presenting cells and antibody-secreting cells in mild, but not hospitalized COVID-19**
40 **patients. This early-stage SARS-CoV-2-specific response was predominantly characterized**
41 **by substantially expanded clonotypes of CD4 and less of CD8 T cells. The early-stage**
42 **responses of T cells and dendritic cells were highly predictive for later seroconversion and**
43 **protective antibody levels after three weeks in mild non-hospitalized, but not in hospitalized**

44 **patients. Our systemic analysis provides the first full picture and early-stage trajectory of**
45 **highly coordinated immune responses in mild COVID-19 patients.**

46 **Keywords**

47 **COVID-19; non-hospitalized; Systems Immunology; Immunology.**

48 **Introduction**

49

50 The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
51 respiratory syndrome corona virus 2 (SARS-CoV-2) has widely affected human health and
52 socioeconomic layers in societies worldwide. Although vaccines, a key factor in fighting against
53 COVID-19, have been rapidly developed and vaccination rollout has been successfully
54 implemented in many countries¹, a full understanding of the complexity of immune responses
55 leading to different clinical outcomes of natural SARS-CoV-2 infection still remains incomplete. The
56 immunopathology underlying severe COVID-19 has been thoroughly studied over the last 18
57 months, including antibody responses, cellular immune subsets, cytokines and chemokines that
58 were linked to characteristics and outcome of the disease²⁻⁶. However, with few exceptions⁷,
59 relatively little is known about the details of the immune response in mild and asymptomatic
60 COVID-19 patients.

61

62 Using profiling analyses of immune cell subsets, several studies have identified crucial alterations
63 in severe COVID-19 patients as compared to hospitalized patients with moderate disease,
64 convalescent and healthy controls. These studies, which mainly utilized flow cytometry or single-
65 cell mRNA sequencing for deep immune cell analysis, have demonstrated a wide spectrum of
66 abnormal immune responses to SARS-CoV-2^{4,8-10}. However, asymptomatic and/or mild COVID-19
67 patients have only rarely been included in these studies to draw conclusions. Thus, it remains
68 elusive whether certain immune alterations observed in severe COVID-19 patients also occur in
69 SARS-CoV-2 PCR-positive non-hospitalized patients with asymptomatic or mild disease. It is also
70 unclear, whether early protective immune signatures are identifiable in asymptomatic or mild non-
71 hospitalized patients, and how such immune signatures might compare to more severe

72 hospitalized COVID-19 patients and healthy subjects. Overall, the connection between the
73 orchestration of the early immune responses after natural infection with SARS-CoV-2 and the
74 resulting COVID-19 disease severity remains to be fully understood.

75

76 Several studies have included asymptomatic and mild COVID-19 patients in cross-sectional
77 analyses. For example, antibody responses and several cytokines/chemokines have been
78 analyzed in asymptomatic versus symptomatic subjects¹¹. Also, SARS-CoV-2-specific and
79 functional memory T cells have been detected in recovered asymptomatic and mild COVID-19
80 patients¹² or in recovered patients with undefined disease severity¹³. Such cross-sectional studies
81 were critical to identify dysregulated immune factors that contribute to severe COVID-19. However,
82 the isolated analysis of specific cellular immune subsets or of cytokines and antibody responses
83 alone will only allow for a partial understanding of the coordination of the early immune response
84 and trajectories following natural infection with SARS-CoV-2. Furthermore, due to different kinetics
85 of immune responses among various patient groups, only a head-to-head comparison in a
86 longitudinal, prospective study design can guarantee the comparability of observations between
87 different study groups. This was only partially addressed in a recent longitudinal COVID-19 project,
88 where the dynamic responses of various immune cells were investigated in asymptomatic, mild
89 and hospitalized COVID-19 patients⁷. A comprehensive picture still remains incomplete because
90 relevant observations and conclusions were based on various aggregated cohorts that were
91 sampled at different time points, thus suffering from heterogeneous disease severity classification
92 criteria, which were not strictly aligned.

93

94 In our longitudinal cohort characterized by a parallel and prospective study design, we sought to
95 address the open questions regarding the kinetics, the differentiation, the quality and the evolution
96 of early immune responses in mild versus asymptomatic and hospitalized COVID-19 patients
97 following recent infection with SARS-CoV-2. To this end, we simultaneously analyzed 484 immune
98 subsets and combinations of 36 lineage and functional markers in three flow cytometry panels, 24

99 serological cytokine/chemokine markers, serological antibody titers to SARS-CoV-2 Spike (S), S-
100 receptor binding domain (RBD), S-N-terminal domain (NTD) and Nucleocapsid (N), angiotensin-
101 converting enzyme 2 (ACE2) binding inhibition to S and S-RBD as surrogate for antibody
102 neutralization capacity, and T-cell receptor beta (TCRb) repertoire sequencing in a longitudinal
103 analysis with 220 samples. Key findings of our integrated analysis of all immune parameters
104 suggested a highly-coordinated early-stage immune response including both innate and adaptive
105 immune cells in mild non-hospitalized COVID-19 patients only. These early cellular response
106 profiles were strongly correlated with a sufficient protective antibody production three weeks later.
107 Both CD4⁺ and CD8⁺ T cell responses were mounted already very early after SARS-CoV-2
108 infection and showed an unexpected predominance of CD4⁺ SARS-CoV-2-specific TCRb
109 clonotypes. Such a comprehensive, simultaneous and integrated analysis of various immune
110 features in a longitudinal cohort using a systems-immunology strategy as we and others
111 suggested^{14,15} helps to draw an unprecedented full picture of immune responses among mild non-
112 hospitalized COVID-19 patients.

113

114 Results

115 Serological and whole blood count analysis distinguishing hospitalized from 116 mild and asymptomatic COVID-19 patients

117

118 We established the longitudinal Predi-COVID cohort¹⁶ in Luxembourg during the first wave of the
119 current pandemic with the aim to gain a deep and systematic understanding of the early antiviral
120 immune response across the full spectrum of COVID-19 disease phenotypes (**Fig. 1a**). All patients
121 received a diagnosis of COVID-19 confirmed by the SARS-CoV-2 PCR test through the national
122 healthcare system and were then included into Predi-COVID with a delay of maximum 3 days after
123 clinical PCR diagnosis. According to available clinical metadata, patients were stratified into
124 asymptomatic (n=14), mild to moderate (n=63; referred to as “mild” patient group in **Fig. 1a** and
125 thereafter), and hospitalized (n=15) subgroups for further analyses. All patients (n=92) were
126 sampled on the day of inclusion (defined as “day 1”) and three weeks after inclusion (“day 21”).
127 The group of mild COVID-19 patients also contained 11 patients with self-reported shortness-of-

128 breath symptoms that could not be confirmed by a physician and therefore could not be classified
129 as moderate patients following the NIH guideline. We also included control individuals (n=26) from
130 patients' households, who were sampled on day 1 and day 14. While the age range was not
131 different for asymptomatic and mild patients as compared to household controls (**Supplementary**
132 **Table 1, Fig. 1b**), hospitalized patients were older than mild patients (median, ~57 vs. ~38 years of
133 age) and controls (**Fig. 1b**). The BMI was not different among any of the analyzed groups
134 (**Supplementary Table 1**). In general, more males were included in each of the patient subgroups
135 (between 57% and 69%), while only around 30% of household controls were male participants
136 (**Supplementary Table 1**). No comorbidity information was available for hospitalized patients and
137 household controls. For the other patient groups, the prevalence of comorbidities (asthma, chronic
138 hematologic disease, obesity and uncomplicated diabetes) was higher among mild than among
139 asymptomatic patients (5% to ~8% among mild vs. none among asymptomatic patients)
140 (**Supplementary Table 1**).

141

142 A whole blood count analysis was used to further characterize COVID-19 patients on day 1. We
143 found no significant difference between asymptomatic and mild patients in any of the tested 17
144 general blood count parameters (**Supplementary Table 1, Supplementary Fig. 1**). However,
145 hospitalized patients showed a remarkable difference compared to mild or asymptomatic patients
146 as demonstrated in the principal component analysis (PCA) plot based on the analysis of whole-
147 blood-count parameters (**Supplementary Fig. 1a**). In line with the reports by others¹⁷, the
148 frequency of lymphocytes was substantially decreased in hospitalized patients compared to the
149 two other patient groups (**Supplementary Fig. 1b**), while CRP was significantly elevated in
150 hospitalized patients only (**Supplementary Fig. 1c**). Furthermore, hospitalized patients showed an
151 increased number of white blood cells (WBC) (**Supplementary Fig. 1d**). This shift was mainly
152 reflected by an increase in the number and frequency of both monocytes and granulocytes
153 (**Supplementary Fig.1e-h**). Both the red blood cell count and the hematocrit were modestly but
154 significantly decreased, accompanied by a slightly higher number of platelets in hospitalized

155 patients (**Supplementary Fig. 1i-j**). Although significantly enhanced, the number of platelets was
156 still within the normal range in most of the hospitalized patients (**Supplementary Fig.1j**).

157

158 As expected, on day 1 we did not observe a significant increase in IgG antibody levels to SARS
159 CoV-2 S, CoV-2 RBD, CoV-2 NTD and CoV-2 N in the groups of asymptomatic and mild patients
160 compared to controls (**Fig. 1c-f**). In contrast, while only 48% and 43% of the mild patients showed
161 slightly increased IgG levels, 93% and 75% of the hospitalized patients already displayed
162 significantly enhanced IgG titers to CoV-2 S and N antigens respectively. Three weeks later, we
163 observed a significant increase in IgG levels to all four antigens also in the mild patient group
164 compared to household controls together with a further enhancement of IgG antibody levels in
165 hospitalized patients. The positivity rate for IgG antibodies to CoV-2 S, CoV-2 RBD, CoV-2 NTD
166 and CoV-2 N reached up to 89% among mild and 100% among hospitalized patients at day 21.
167 Asymptomatic patients had a lower positivity rate for IgG against CoV-2 S/S-RBD (67%) and CoV-
168 2 N (75%) than mild patients at day 21 (**Fig. 1c-e**). IgG antibodies against CoV-2 NTD were in
169 general much lower in asymptomatic and mild patients, only reaching very high levels of 100%
170 positivity in the hospitalized group at day 21 (**Fig. 1f**). Next, we tested the functional capacity of the
171 induced antibodies against SARS-CoV-2 in a surrogate virus neutralization assay. The assay
172 analyzes the capacity of antibodies to inhibit the binding of labelled recombinant ACE2, the human
173 receptor for SARS-CoV-2, to CoV-2 S or CoV-2 RBD in a multiplex high-throughput format. In line
174 with the serology findings on day 1 (**Fig. 1c, d**), hospitalized patients already showed blocking
175 antibodies that interfered with ACE2 binding to CoV-2 S or CoV-2 RBD at this early stage (**Fig. 1g,**
176 **h**). On day 21, also mild patients had developed a significant inhibitory serologic capacity to block
177 ACE2 binding to CoV-2 S or CoV-2 RBD relative to household controls. Such an increase in ACE2
178 blocking was not seen in the asymptomatic group (**Fig. 1g, h**), which was also lower in IgG titers
179 against CoV-2 S or CoV-2 RBD (**Fig. 1c, d**). In line with this notion and as reported by others¹⁸,
180 IgG antibody titers against both CoV-2 S and CoV-2 RBD, were highly correlated (spearman

181 $r=0.89$ and 0.82 for CoV-2 S and RBD, respectively) with the inhibitory capacity of sera across all
182 patient categories of COVID-19 severity (**Fig. 1i, j**).

183 **Early-stage highly-coordinated innate and adaptive immune responses in** 184 **mild COVID-19**

185

186 As shown above, clinical and routine laboratory data as well as in depth serologic profiling of
187 SARS-CoV-2-specific antibody responses already distinguished hospitalized COVID-19 patients
188 from mild or asymptomatic patients and control individuals. However, these profiling analyses are
189 not sufficient to further differentiate non-hospitalized clinical phenotypes of COVID-19. Thus, we
190 aimed to explore the full complexity of innate and adaptive cellular immune signatures that
191 orchestrate the early response to SARS-CoV-2 infection across the full spectrum of COVID-19
192 disease phenotypes. We systematically investigated 484 cellular immune subsets or combinations
193 of various lineage and functional markers by three different staining panels using 18-color flow
194 cytometry (for general gating strategy, see **Supplementary Fig. 2**; for cellular markers analyzed,
195 refer to **Supplementary Table 2**) on day 1 and at the follow-up visit (day 14 for controls or day 21
196 for patients). When compared with household controls, asymptomatic patients displayed no
197 obvious change in all the analyzed 484 immune profiles at day 1 (**Supplementary Fig. 3a**).
198 Interestingly, at day 21, ICOS⁺ CD8 T cells were the only significantly changed immune subset with
199 a decrease in the frequency among CD8 T cells from asymptomatic patients (**Supplementary Fig.**
200 **3b, c**). Although primarily known for its critical role in CD4 T cell and lymph node germinal center
201 formation, studies in ICOS-deficient patients have also indicated a role for ICOS in CD8 effector
202 functions during primary antiviral immunity^{19,20}.

203

204 We next used PCA to show that deep immune profiling was only able to partition hospitalized
205 patients at day 1 from all other groups investigated, but not mild COVID-19 patients from any
206 household control (day 1 and day 14) (**Fig. 2a**). Then we asked whether specific immune subsets
207 were differentially present in mild COVID-19 patients compared to age-matched household
208 controls at day 1 (**Fig. 2b**). We observed differences in the frequency of several CD8 T cells

209 subsets, such as Ki67⁺, CD38⁺, and HLADR⁺CD38⁺, representing proliferating, activated and
210 antigen-specific responsive CD8 T cells respectively that were significantly enhanced in mild
211 COVID-19 patients (**Fig. 2c-e**). The profile included an increase of both Tbet-dependent
212 (Tbet⁺Ki67⁺) and -independent (Eomes⁺Ki67⁺) responsive CD8 T cells (**Fig. 2f-h**). Also the fraction
213 of proliferating CD4 T cells, especially, Th1-responsive (Tbet⁺Ki67⁺) CD4 T cells was already
214 enhanced early on in mild patients on day 1 (**Fig. 2i, j, Supplementary Fig. 4a**). In parallel, the
215 frequency of antigen presenting cells (APCs) and antibody secreting cells, such as mature
216 dendritic cells (HLADR⁺CD38^{high}DCs) and short-lived plasmablasts (CD27⁺CD38^{high}), was
217 increased in mild patients (**Fig. 2k, l, m, Supplementary Fig. 4b, 4c**). Notably, using the unique
218 power of our longitudinal cohort design and the simultaneous comprehensive analysis of both
219 cellular immune subsets and serological responses, allowed the successful prediction of anti-
220 SARS-CoV-2 antibody responses at day 21. The frequency of activated CD38⁺ CD8 T cells and of
221 mature DCs measured at day 1 was highly predictive for the degree of the serological titers of anti-
222 SARS-CoV-2 N IgG at day 21 among asymptomatic and mild patients (**Fig. 2n, o**). On the
223 contrary, it is noteworthy that neither the frequency of CD38⁺ cells among CD8 T cells nor of
224 mature DCs at day 1 was significantly correlated to the even higher titers of SARS-CoV-2 N IgG
225 (**Fig. 2l, m**) in the group of hospitalized COVID-19 patients at day 21 (**Fig. 2p, q**). This finding
226 indicates that the progression and deterioration of COVID-19 is averted only in the presence of a
227 highly coordinated interplay of early cellular innate and adaptive immune responses, which are
228 strongly correlated to the subsequent production of protective antibody titers against SARS-CoV-2.

229

230 Now switching to day 21 after inclusion, we followed the evolution of the early cellular immune
231 response. On day 21, mild COVID-19 patients were characterized by an enhanced cytotoxic CD8
232 T cell (GZMB⁺) response, especially of terminally differentiated responsive CD8 T cells (CD45RO⁻
233 Ki67⁺) (**Supplementary Fig. 5a-c**). CD4 T cells also showed similar changes after three weeks.
234 The frequencies of CD4 T cells expressing CD57 and GZMB as well as of CD45RO and CD57
235 double-positive CD4 T cells were also significantly enhanced in mild patients compared to

236 household controls (**Supplementary Fig. 5d-f**). Notably, the frequency of GZMB⁺ CD4 cytotoxic T
237 cells showed a trend to be elevated ($p=0.053$, Kruskal-Wallis test including multiple-group
238 correction) already on day 1 (**Supplementary Fig. 5e**). The CD57 expressing CD4 T cells
239 detected on day 21 appeared to be mainly cytotoxic effector cells since the percentage of
240 GZMB⁺CD57⁺ cells was also significantly enhanced among CD4 T cells (**Supplementary Fig. 5g**).
241 Although CD57 is regarded and known as a T-cell senescence marker, CD57⁺ T cells, similar to
242 PD-1⁺ T cells²¹, were apparently still functional during the acute phase of COVID-19, thus likely
243 contributing to a sufficient control of the infection in the mild patient group.

244 **Early-stage impaired innate immunity in hospitalized, but not mild patients**

245

246 In the analyses presented hitherto, we parsed primarily early immune signatures in mild COVID-19
247 patients in relation to household controls on day 1 and day 21. Yet, the analysis of early cellular
248 responses and later antibody responses showed a positive correlation only in mild and
249 asymptomatic, but not in hospitalized patients (**Fig. 2n-q**). This finding prompted us to further
250 analyze this aspect. Thus, we asked whether any additional early immune signatures observed in
251 mild patients were significantly different from hospitalized patients and determined the immune
252 signatures that were significantly upregulated or downregulated in mild versus hospitalized COVID-
253 19 patients on day 1 (**Fig. 3a**). As shown in the volcano plot analyses, major differences were
254 present primarily among innate immune cells, such as monocytes, dendritic cells (DC) and natural
255 killer (NK) cells, and to a lesser extent also among B and T cells. Compared with hospitalized
256 patients, mild COVID-19 patients showed a much higher frequency (~40% in mild patients vs.
257 ~10% in hospitalized patients) of non-classical monocytes (ncMono, HLADR⁺CD38⁻)²². The non-
258 classical monocytes were not only higher in frequency among the mild patients, but expressed also
259 higher levels of critical functional markers, such as CD86/CD80 double-positivity (**Fig 3b-d**), PD-L1
260 and CD13 (**Supplementary Fig. 4d, Supplementary Fig.6a, b**). Similar to monocytes, the
261 frequency of antigen-presenting cells (APC) such as plasmacytoid DC (pDC) and myeloid DC
262 (mDC) was significantly higher in mild patients versus hospitalized ones (**Fig. 3a, d-f**). It is

263 noteworthy that the frequency of ncMono and mDC (**Fig.3b, f**) was also slightly lower in mild
264 patients versus household controls, indicating a disease severity-related effect and further
265 supporting the involvement of both cell types in early protective immune responses of COVID-19.
266 Although mature DC were higher in both mild and hospitalized patients (**Fig. 2I**), the frequency of
267 CD86⁺CD80⁺ functional cells (**Fig. 3g, h**) and of CD13⁺ cells (**Supplementary Fig. 6c**) among total
268 DC was decreased in hospitalized patients only, thus indicating a reduction in phagocytic and
269 antigen-presenting capacity of individual DC²³. These findings signify one of the advantages of our
270 study, where we analyzed not only lineage, but also functional markers, thus allowing a better
271 comprehension and interpretation of seemingly conflicting results. In line with the notion of reduced
272 APC functions, the downstream events of APC activating responses, the frequency of activated
273 CD4 T cells (CD27⁺ICOS⁺) and the ICOS MFI among CD8 T cells were decreased only in
274 hospitalized, but not mild patients (**Supplementary Fig. 6d, e**). Furthermore, the frequency of NK
275 cells was also significantly decreased only in hospitalized, but not in mild patients relative to
276 household controls (**Fig 3i, j**). In line with the overall compromised innate immune cell profile,
277 critical senescence and exhaustion markers such as KLRG1 and PD-1 were enhanced among
278 several subsets of NK cells in hospitalized patients only (**Fig. 3k, Supplementary Fig. 4e,**
279 **Supplementary Fig. 6f, g**).

280

281 In contrast to the compromised innate immune cell compartment, the expression levels of CD86
282 and of PD-L1 among class-switched memory B cells were substantially enhanced in hospitalized
283 COVID-19 patients versus both household controls and mild patients at day 1 (**Supplementary**
284 **Fig. 6h,i**). Considering these results together with the high SARS-CoV-2-specific IgG levels, the
285 ACE2 blocking capacity of patient serum and the high frequency of plasmablasts, we concluded
286 that antibody-secreting cells were not impaired in both mild and hospitalized patients at the very
287 early stage (on day 1), thus leading to a robust antibody response in both patient groups after
288 three weeks.

289

290 We next sought to understand whether the impaired innate immune cell response in hospitalized
291 patients was paralleled by early deviated CD8 T cell profiles. Although the intensity (MFI) of ICOS
292 on CD8 T cells was decreased (**Supplementary Fig. 6e**), the frequency of ICOS⁺ CD8 T cells was
293 unchanged (**Supplementary Fig. 3c**) and the frequency of CD40L⁺ and PD-1⁺GZMB⁺ cells among
294 CD8 T cells was even significantly enhanced in hospitalized patients on day 1 (**Supplementary**
295 **Fig. 6j, k**). Furthermore, since the frequency of CD8 T cells expressing other key functional
296 markers, such as Ki67 and CD38, as well as the frequency of CD8 T cells co-expressing HLA-DR
297 and CD38, Tbet and Ki67, as well as Eomes and Ki67 was not decreased in hospitalized patients
298 (**Fig. 2c-g**), the functional antiviral capacity of CD8 T cells was most likely equally robust in
299 hospitalized and mild COVID-19 patients. Overall, these data indicate that the major deficiencies
300 observed in hospitalized COVID-19 patients on day 1 were impaired innate immune cells and APC
301 functions rather than adaptive T- and B-cell functions.

302

303 The differences in cellular immune signatures described above between mild and hospitalized
304 patients were only significant on day 1, but not after three weeks on day 21. This indicates that
305 various immunological signatures, which are reduced in hospitalized patients on day 1, are unique
306 to the mild clinical phenotype of COVID-19 and may thus be crucial protective factors at an early
307 stage of the disease.

308 **Early-stage temporary and reversible elevation of IP10 and IFN β in mild** 309 **COVID-19 patients**

310

311 To gain further insight into the coordinated early immune response of COVID-19, we analyzed 24
312 different cytokines, chemokines and growth factors on both day 1 and day 21 in sera of all patient
313 and control groups. Interestingly, at day 1, we observed increased levels of interferon gamma-
314 inducible protein 10 (IP10/CXCL10) in hospitalized patients and in the mild patient group (**Fig. 4a,**
315 **b**). Unexpectedly, a similar regulation was found for the type I-interferon IFN β , which was
316 previously reported to be undetectable in severe COVID-19 patients at around 10 days after
317 symptom onset²⁴. Both hospitalized and mild patients showed a significant increase of IFN β

318 compared to controls at day 1 (**Fig. 4c**). While the levels of IP10 and IFN β showed only a
319 temporary and reversible increase among mild patients, declining to normal levels at day 21, this
320 was not the case in hospitalized patients, where both IP10 and IFN β levels remained elevated after
321 three weeks (**Fig. 4c**). These results point to a crucial and dynamic role of IP10 and IFN β , which is
322 tightly regulated during the early stage of protective immune responses in COVID-19 patients. This
323 notion is also supported by the fact that levels of IP10 and IFN β were significantly correlated with
324 the frequency of mature DCs among all the analyzed patients at day 1 of the Predi-COVID study
325 (**Fig. 4d, e**). On day 21, none of the 24 circulating immune analytes showed a significant change in
326 the mild patient group versus household controls at day 14 (**Supplementary Fig. 7a**). We also
327 could not observe any significant change in the tested cytokine/chemokine levels among
328 asymptomatic patients, neither on day 1 nor on day 21 (**Supplementary Fig. 7b, c**). The increase
329 of IP10 in mild and hospitalized COVID-19 patients appears to be independent of IFN γ , which was
330 only elevated in the hospitalized patient group (**Fig. 4c, f, g**) and remained significantly higher in
331 hospitalized patients, but still within the normal range for most of the patients (**Fig. 4g**). Overall, the
332 IP10 and IFN β signature in mild COVID-19 patients was characterized by early dynamic changes
333 with a strong increase at day 1 and a contraction to normal levels at day 21, while the levels in
334 hospitalized patients remained high.

335

336 With regard to other circulating immune factors, we found a significant increase in plasma levels of
337 eosinophil chemotactic protein (eotaxin-1/CCL11), vascular endothelial growth factor A (VEGFA),
338 IL-6 and IL-10 only in hospitalized patients at day 1 (**Fig. 4h-k**). The enhanced levels of IL6 and
339 the regulatory cytokine IL10 in hospitalized versus mild patients on day 1 were still mostly seen
340 within the normal range (**Fig. 4j, k**). The increased level of IL10 was in line with an increased
341 percentage of FOXP3⁺ Tregs in both mild and hospitalized patients at day 1 (**Fig. 4l**). In
342 conclusion, on day 21 after inclusion into the study, most of the analyzed cytokines/chemokines
343 that were elevated early in mild patients had returned to normal levels and waned in hospitalized
344 patients. Only IFN γ , IFN β and IP10/CXCL10 remained higher in hospitalized patients than mild

345 patients and controls on day 21 (**Supplementary Fig. 7d**). The only exception was the Th2
346 cytokine IL5, which was not different on day 1, but modestly increased in mild patients at day 21,
347 while hospitalized patients exhibited very low IL5 levels at this point (**Supplementary Fig. 7e**).

348

349 **Early-stage dominant expansion of CD4+ SARS-CoV-2-specific T cells in mild** 350 **patients**

351

352 To identify the T-cell response on a broader scale, we performed TCRb sequencing analysis
353 among 45 mild patients versus 8 asymptomatic subjects and 21 household controls on days 1 and
354 21. Aging has a strong impact on the TCR repertoire²⁵. As expected, sample clonality, the inverted
355 normalized diversity index, was significantly correlated with the age of all analyzed subjects (**Fig.**
356 **5a**). Since a decrease in TCR diversity was previously associated with aging and impaired
357 immunity against influenza virus infection and other diseases^{26,27}, we sought to compare the TCR
358 diversity between different groups. The productive clonality of the sequenced TCRb repertoire was
359 increased in mild patients at day 21 versus household controls (**Fig. 5b**). At day 21, only the usage
360 of one specific V gene (TCRBV06-07) was significantly underrepresented in mild patients
361 compared to household controls (**Fig. 5c**). Notably, the SARS-CoV-2-specific T-cell clonotypes
362 were substantially expanded (~6 times higher than in household controls) among mild patients
363 already at day 1, as reflected by clonal breadth and depth²⁸, and maintained at day 21 (**Fig. 5d,**
364 **e**). These results indicate a key functional role of early-responsive SARS-CoV-2-specific T cells in
365 mild COVID-19 patients. Completely unexpected, mainly CD4 SARS-CoV-2-specific T cells were
366 expanded among mild patients at day 1, with an average frequency of CD4 SARS-CoV-2-specific
367 TCR clonotypes that was six times higher than that of CD8 T cells among mild patients (**Fig. 5f-h**).
368 This finding was in line with a trend for increased frequency of GZMB⁺ cells among CD4 Tconv
369 cells, but not among CD8 T cells in mild patients versus controls on day 1 (**Supplementary Fig.**
370 **5a, e**). At day 21, CD4 SARS-CoV-2 specific TCR clonotypes continued to dominate over CD8
371 clonotypes to a similar extent in mild patients (**Fig. 5g, h**). The expansion of CD4 or CD8 SARS-
372 CoV-2-specific T cells was highly correlated with the frequency of responsive ICOS⁺Ki67⁺ cells

373 among total CD4 T cells or total CD8 T cells in both asymptomatic and mild patient groups at day 1
374 (**Fig. 5i, j**). These data highlight a crucial role of early-expanding SARS-CoV-2-specific T cells,
375 especially of the CD4⁺ phenotype, for subsequent coordinated antiviral immune responses. Thus,
376 our findings are not only in line with, but add significantly novel aspects to earlier studies that
377 identified SARS-CoV-2-specific T cells early after diagnosis, but without correlating their findings
378 to a severity stratification of COVID-19 patients nor performing further sub-analysis of CD4 and
379 CD8 T cells²⁹.

380 Discussion

381

382 In May 2020, a mass PCR screening program was implemented on a population-wide level in
383 Luxembourg³⁰, which allowed us to get unique access to PCR-positive asymptomatic and mild
384 non-hospitalized COVID-19 patients and to prospectively recruit them into the longitudinal Predi-
385 COVID study that was initiated simultaneously¹⁶. This empowered us to analyze a comprehensive
386 picture of distinct early-stage protective immune signatures in mild COVID-19 patients versus
387 hospitalized patients, asymptomatic individuals and healthy controls during the first waves of the
388 pandemic. We evaluated more than 500 cellular and soluble markers of the immune response in
389 the peripheral blood of all study participants twice in the early time window after infection.
390 Furthermore, we performed systematic TCRbeta variable chain sequencing at the identical time
391 points in our cohort. Thus, our work provides an important resource based on the unique
392 opportunity to fully explore and understand all essential facets of the early-stage and dynamic
393 immunological changes following recent SARS-CoV-2 infection in mild COVID-19 patients, using
394 an unbiased and prospective approach.

395

396 So far, the immune response in COVID-19 patients has only been investigated in a few longitudinal
397 cohort studies^{17,31-34}. These studies concentrated on different time windows and they usually put
398 their major focus on one or two selected immunological aspects, which makes it challenging to
399 directly compare them with our results. In line with another recent longitudinal study from the UK⁷,
400 we also observed enhanced early-stage CD8 T cells and plasmablast responses in mild COVID-19

401 patients. In contrast to that published work, our current study now provides not only information on
402 the number and frequency of a wide spectrum of immune subsets in peripheral blood, but also on
403 the functionality of individual immune cell types. We found both early-stage Tbet-dependent and -
404 independent CD8 T cell responses among mild COVID-19 patients. Distinct from the UK cohort⁷,
405 we observed robust early-stage responses of CD4 T cells with a profoundly enhanced frequency of
406 type-I-IFN-dependent Tbet⁺Ki67⁺ CD4 T cells. As additional unique result of our study, mature DC
407 expressing all key functional markers were strongly enhanced early on in mild but not hospitalized
408 patients. The notion that early coordinated DC and CD4/CD8 T cell responses have indeed a
409 functional role in SARS-CoV-2-specific immunity was further supported by the correlation between
410 mature DC and CD38⁺CD8 T cells at early stage (day 1) with antibody responses three weeks later
411 (day 21). Consistent with the observed early-stage CD4 and CD8 T cell responses, we found a
412 substantial expansion of SARS-CoV-2-specific T-cell clonotypes, predominantly of CD4 T cells, in
413 mild COVID-19 patients already at day 1. Since we observed enhanced DC and coordinated CD4
414 and CD8 T cell responses very early on among mild COVID-19 patients, at most three days after
415 PCR diagnosis, the concept of bystander CD8 T cell responses⁷ might need to be adapted. Our
416 findings suggest that appropriate and highly coordinated early-stage DC and antigen-specific T cell
417 responses are crucial for guiding the development of a protective adaptive immune response at
418 later stage, which is key for a long-term favorable outcome in non-hospitalized mild COVID-19
419 patients.

420

421 Another important observation that is very much in line with the coordinated early-stage DC and
422 antigen-specific CD4 and CD8 T cell responses was the strong early induction of the type-I
423 interferon IFN β in both mild and hospitalized COVID-19 patients. However, in contrast to
424 hospitalized patients, the early rise of IFN β levels in mild patients was followed by a decrease to
425 normal levels three weeks later. Such a contraction of IFN β was not seen in hospitalized patients,
426 where the levels remained high three weeks later, thus indicating a possible dysregulation in more
427 severe COVID-19 phenotypes. Indeed, previous studies had demonstrated impaired type-I

428 interferon responses in severe COVID-19 patients^{24,35,36}. Our current results on early induction and
429 contraction of IFN β levels in mild COVID-19 patients were further confirmed by a strong correlation
430 between the frequency of mature DC, one of the main producers of type-I interferon³⁷, and the
431 circulating IFN β levels on day 1. Our data suggest a protective role of the type-I interferon IFN β
432 that may be crucial during the very early stage of COVID-19 after recent exposure to SARS-CoV-2.
433 The results of an early time-dependent induction of IFN β in our study are in line with studies on
434 genetic and autoimmune defects in the type-I IFN pathway that were correlated to severe COVID-
435 19^{24,35,36}. These findings have prompted to propose early and transient intervention with
436 recombinant type-I IFN such as IFN β as a treatment option in severe COVID-19 patients³⁸. Parallel
437 to IFN β , we observed substantially enhanced early IP10/CXCL10 levels without other signs of
438 systemic inflammation in mild patients. After three weeks, IP10 levels had declined to the normal
439 range in mild, but not in hospitalized COVID-19 patients, thus indicating that a temporary early-
440 stage enhancement of IP10 may be beneficial in mild COVID-19. IP10, previously known to
441 exclusively bind to CXCR3, has recently been identified as a high-affinity agonist for the anti-
442 inflammatory atypical chemokine scavenger receptor ACKR2/D6^{39,40}. Thus, during the coordinated
443 early anti-SARS-CoV-2 immune response in mild patients, IP10 might play a role in limiting and
444 resolving inflammatory responses. The longer-lasting high levels of IP10 are not unique to severe
445 COVID-19, but occur also in other infectious diseases⁴¹, including SARS, where high levels of IP10
446 were maintained for at least two weeks⁴². Our observations are also in line with previously reported
447 enhanced IP10 levels in symptomatic versus asymptomatic patients during the acute phase of
448 COVID-19¹¹ and sustained levels in hospitalized patients⁴³.

449

450 Notably on day 1, hospitalized COVID-19 patients showed significantly increased levels of vascular
451 endothelial growth factor A (VEGFA), known to be critical in acute lung injury⁴⁴, and of eosinophil
452 chemotactic protein (eotaxin-1/CCL11). Enhanced VEGFA mRNA expression has previously also
453 been demonstrated in the bronchial alveolar lavage fluid of two COVID-19 patients⁴⁵. Furthermore,
454 a significant elevation of VEGFA and eotaxin-1 among both mild and severe COVID-19 patients

455 relative to controls, although without significant difference between the two groups, was reported in
456 a small scale pilot study⁴⁶ and anti-VEGF medication has been investigated to treat COVID-19 in a
457 phase-II clinical trial⁴⁷. Our findings strongly suggest that VEGFA and eotaxin-1 are indeed
458 differentially regulated during the early phase of the immune response in hospitalized, i.e., more
459 severe COVID-19 patients.

460

461 Another crucial observation of our study was an early-stage signature of reduced frequency and
462 functional impairment of innate immune cells, such as non-classical monocytes (ncMono), DC
463 (pDC and mDC) and NK cells, in hospitalized COVID-19 patients only. Both the frequency of
464 ncMono and the expression of their key functional markers, such as CD80, CD86, PD-L1 and
465 CD13, were significantly reduced in hospitalized patients. Notably, although the frequency of
466 mature DC was induced early on in both mild and hospitalized patients, their functional subsets,
467 such as CD86-CD80+ cells among total DC, were substantially reduced only in the hospitalized
468 patients. In addition, similar findings were also made in hospitalized patients regarding the reduced
469 frequency of several NK cell subsets, paralleled by a substantial enhancement in the expression of
470 the inhibitory and terminal differentiation marker KLRG1 on NK cells. Thus, our data of impaired
471 innate immune cell signatures in hospitalized, but not mild COVID-19 patients confirm previous
472 findings of impaired innate immunity in severe or critically ill COVID-19 patients^{48,49}. Furthermore,
473 our results are in line with the decreased frequency of pDC in hospitalized patients versus control
474 subjects, which was revealed through a longitudinal single-cell RNA sequencing analysis³⁴.
475 However, none of the previous studies has addressed the differences in early-stage innate
476 immune cell responses between non-hospitalized (i.e., asymptomatic and mild patients) and
477 hospitalized COVID-19 patients. Here, in contrast to the coordinated response in mild patients, our
478 data revealed major innate immune cell dysregulations and impairment exclusively in hospitalized
479 patients.

480

481 With few exceptions⁷, much less was known so far about protective anti-SARS-CoV-2 immune
482 responses in non-hospitalized mild COVID-19 patients. Our current work now provides a first
483 resource that systematically describes the evolving trajectory of highly coordinated early-stage
484 protective immune responses in mild COVID-19 patients. Based on a sufficiently-powered sample
485 size (63 mild participants) and on the prospective longitudinal nature of our study, we discovered
486 the frequency of CD38⁺ among CD8 T cells and of mature DCs at an early disease stage
487 (maximum three days post-PCR diagnosis) to be highly robust and even better predictors of
488 ensuing humoral responses at three weeks than early plasmablast responses, pointing to a critical
489 role of DC activation in coordinating very early antigen-specific T cell and later antibody responses.
490 Thus, the immune signatures identified in our study bear the potential to be extrapolated to predict
491 protective immune responses in vaccinated people early on. In fact, our discoveries are in line with
492 a recent report showing that mRNA vaccination induces rapid abundant antigen-specific CD4 T-cell
493 responses in SARS-CoV-2 naïve participants following the first dose⁵⁰, which phenocopies our
494 findings in mild COVID-19 patients, thus indicating that the discoveries of our study will have a
495 more general impact for understanding and further dissecting SARS-CoV-2-specific immunity. In
496 our cohort, we were unable to observe a clear protective immune signature in the peripheral blood
497 of PCR-positive asymptomatic individuals throughout all cellular and humoral immune analyses.
498 Although the sample size was relatively small in our asymptomatic category, the most likely
499 explanation for this result is a more prominent role of a tissue-resident rather than a systemic
500 immune response, where anti-viral immunity mainly occurs locally through pre-activated innate
501 immune stimulation in epithelial cells of the upper airways, as recently shown in a pediatric cohort⁵¹.

502

503 **Acknowledgements**

504

505 We first would like to acknowledge the active involvement of all the anonymous participants in the
506 Predi-COVID cohort. We are also thankful for the excellent support of the recruitment team of the
507 Predi-COVID cohort from CIEC of LIH. The Predi-COVID study is supported by the Luxembourg

508 National Research Fund (FNR) (Predi-COVID, 14716273) and the André Losch Fondation. We
509 also highly appreciate the expert support of the IBBL processing and biorepository teams. F.Q.H.
510 was partially supported by FNR CORE programme grant (CORE/14/BM/8231540/GeDES), FNR
511 AFR-RIKEN bilateral programme (TregBAR, 11228353, F.Q.H. and M.O.) and PRIDE programme
512 grants (PRIDE/11012546/NEXTIMMUNE and PRIDE/10907093/CRITICS). C.H. was partially
513 supported by the FNR fast-track call COVID-19/2020-1/14703957/COV-Immun.

514

515 Author contributions

516

517 C.C. designed and performed the experiments, performed data analysis and drafted the
518 manuscript. S.C., O.D., F.H., M.K. and W.A. performed parts of experiments. I.E. and A.F.
519 coordinated the cohort recruitment. C.S., C.H., G.S., T.A. and K.G. collected samples and
520 performed parts of experiments. A.C. and M.V. collected clinical data, quality control and data
521 management. C.L.C. and I.M.K. analyzed the TCR repertoire data. A.S., A.D.S., A.C., F.B. and
522 G.F. provided substantial insights and supervision into the project. F.Q.H. and M.O. conceived and
523 oversaw the whole project and wrote and finalized the manuscript.


524 References

- 525 1 Mathieu, E. *et al.* A global database of COVID-19 vaccinations. *Nature Human Behaviour* **5**, 947-953,
526 doi:10.1038/s41562-021-01122-8 (2021).
- 527 2 Kuri-Cervantes, L. *et al.* Comprehensive mapping of immune perturbations associated with severe COVID-19.
528 *Science Immunology* **5**, eabd7114, doi:10.1126/sciimmunol.abd7114 (2020).
- 529 3 Mathew, D. *et al.* Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic
530 implications. *Science* **369**, eabc8511, doi:10.1126/science.abc8511 (2020).
- 531 4 Arunachalam, P. S. *et al.* Systems biological assessment of immunity to mild versus severe COVID-19
532 infection in humans. *Science* **369**, 1210-1220, doi:10.1126/science.abc6261 (2020).
- 533 5 De Biasi, S. *et al.* Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients
534 with COVID-19 pneumonia. *Nat Commun* **11**, 3434, doi:10.1038/s41467-020-17292-4 (2020).
- 535 6 Zheng, M. *et al.* Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cellular & Molecular*
536 *Immunology* **17**, 533-535, doi:10.1038/s41423-020-0402-2 (2020).
- 537 7 Bergamaschi, L. *et al.* Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early
538 immune pathology distinguish severe COVID-19 from mild disease. *Immunity*,
539 doi:10.1016/j.immuni.2021.05.010 (2021).
- 540 8 Wilk, A. J. *et al.* A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat*
541 *Med* **26**, 1070-1076, doi:10.1038/s41591-020-0944-y (2020).
- 542 9 Saichi, M. *et al.* Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals
543 multi-process defects in antiviral immunity. *Nature Cell Biology* **23**, 538-551, doi:10.1038/s41556-021-00681-
544 2 (2021).
- 545 10 Ren, X. *et al.* COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. *Cell* **184**,
546 1895-1913 e1819, doi:10.1016/j.cell.2021.01.053 (2021).
- 547 11 Long, Q.-X. *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature*
548 *Medicine* **26**, 1200-1204, doi:10.1038/s41591-020-0965-6 (2020).
- 549 12 Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
550 *Cell* **183**, 158-168.e114, doi:<https://doi.org/10.1016/j.cell.2020.08.017> (2020).


- 551 13 Le Bert, N. *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected
552 controls. *Nature* **584**, 457-462, doi:10.1038/s41586-020-2550-z (2020).
- 553 14 Delhalle, S., Bode, S. F. N., Balling, R., Ollert, M. & He, F. Q. A roadmap towards personalized immunology.
554 *npj Systems Biology and Applications* **4**, 9, doi:10.1038/s41540-017-0045-9 (2018).
- 555 15 Davis, M. M., Tato, C. M. & Furman, D. Systems immunology: just getting started. *Nature Immunology* **18**,
556 725-732, doi:10.1038/ni.3768 (2017).
- 557 16 Fagherazzi, G. *et al.* Protocol for a prospective, longitudinal cohort of people with COVID-19 and their
558 household members to study factors associated with disease severity: the Predi-COVID study. *BMJ Open* **10**,
559 e041834, doi:10.1136/bmjopen-2020-041834 (2020).
- 560 17 Tan, L. *et al.* Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal*
561 *Transduction and Targeted Therapy* **5**, 33, doi:10.1038/s41392-020-0148-4 (2020).
- 562 18 Wajnberg, A. *et al.* Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* **370**,
563 1227-1230, doi:10.1126/science.abd7728 (2020).
- 564 19 Takahashi, N. *et al.* Impaired CD4 and CD8 effector function and decreased memory T cell populations in
565 ICOS-deficient patients. *J Immunol* **182**, 5515-5527, doi:10.4049/jimmunol.0803256 (2009).
- 566 20 Bertram, E. M. *et al.* Role of ICOS versus CD28 in antiviral immunity. *Eur J Immunol* **32**, 3376-3385,
567 doi:10.1002/1521-4141(200212)32:12<3376::AID-IMMU3376>3.0.CO;2-Y (2002).
- 568 21 Rha, M. S. *et al.* PD-1-Expressing SARS-CoV-2-Specific CD8(+) T Cells Are Not Exhausted, but Functional
569 in Patients with COVID-19. *Immunity* **54**, 44-52 e43, doi:10.1016/j.immuni.2020.12.002 (2021).
- 570 22 Picozza, M., Battistini, L. & Borsellino, G. Mononuclear phagocytes and marker modulation: when CD16
571 disappears, CD38 takes the stage. *Blood* **122**, 456-457, doi:10.1182/blood-2013-05-500058 (2013).
- 572 23 Villasenor-Cardoso, M. I., Frausto-Del-Rio, D. A. & Ortega, E. Aminopeptidase N (CD13) is involved in
573 phagocytic processes in human dendritic cells and macrophages. *Biomed Res Int* **2013**, 562984,
574 doi:10.1155/2013/562984 (2013).
- 575 24 Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.
576 *Science*, doi:10.1126/science.abc6027 (2020).
- 577 25 Naylor, K. *et al.* The influence of age on T cell generation and TCR diversity. *J Immunol* **174**, 7446-7452,
578 doi:10.4049/jimmunol.174.11.7446 (2005).
- 579 26 Yager, E. J. *et al.* Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and
580 impaired immunity to influenza virus. *J Exp Med* **205**, 711-723, doi:10.1084/jem.20071140 (2008).
- 581 27 Chen, Z. & John Wherry, E. T cell responses in patients with COVID-19. *Nature Reviews Immunology* **20**,
582 529-536, doi:10.1038/s41577-020-0402-6 (2020).
- 583 28 Gittelman, R. M. *et al.* Diagnosis and Tracking of SARS-CoV-2 Infection By T-Cell Receptor Sequencing.
584 *medRxiv*, 2020.2011.2009.20228023, doi:10.1101/2020.11.09.20228023 (2021).
- 585 29 Snyder, T. M. *et al.* Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both
586 Individual and Population Levels. *medRxiv*, doi:10.1101/2020.07.31.20165647 (2020).
- 587 30 Wilmes, P. *et al.* SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening
588 programme in Luxembourg. *The Lancet Regional Health - Europe* **4**, 100056,
589 doi:<https://doi.org/10.1016/j.lanepi.2021.100056> (2021).
- 590 31 Minervina, A. A. *et al.* Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell
591 memory formation after mild COVID-19 infection. *eLife* **10**, e63502, doi:10.7554/eLife.63502 (2021).
- 592 32 Szabo, P. A. *et al.* Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-
593 driven lung inflammation in severe COVID-19. *Immunity* **54**, 797-814.e796,
594 doi:10.1016/j.immuni.2021.03.005 (2021).
- 595 33 Filbin, M. R. *et al.* Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated
596 signatures, tissue-specific cell death, and cell-cell interactions. *Cell Reports Medicine* **2**,
597 doi:10.1016/j.xcrm.2021.100287 (2021).
- 598 34 Liu, C. *et al.* Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. *Cell* **184**,
599 1836-1857.e1822, doi:10.1016/j.cell.2021.02.018 (2021).
- 600 35 Bastard, P. *et al.* Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science* **370**,
601 eabd4585, doi:10.1126/science.abd4585 (2020).
- 602 36 Acharya, D., Liu, G. & Gack, M. U. Dysregulation of type I interferon responses in COVID-19. *Nat Rev*
603 *Immunol* **20**, 397-398, doi:10.1038/s41577-020-0346-x (2020).
- 604 37 Asselin-Paturel, C. & Trinchieri, G. Production of type I interferons: plasmacytoid dendritic cells and beyond.
605 *J Exp Med* **202**, 461-465, doi:10.1084/jem.20051395 (2005).
- 606 38 Vinh, D. C. *et al.* Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-
607 beta. *J Clin Immunol*, doi:10.1007/s10875-021-01068-6 (2021).
- 608 39 Jamieson, T. *et al.* The chemokine receptor D6 limits the inflammatory response in vivo. *Nature Immunology* **6**,
609 403-411, doi:10.1038/ni1182 (2005).

- 610 40 Chevigné, A. *et al.* CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6.
611 *Cancers* **13**, 1054 (2021).
- 612 41 Liu, M. *et al.* CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications.
613 *Cytokine Growth Factor Rev* **22**, 121-130, doi:10.1016/j.cytogfr.2011.06.001 (2011).
- 614 42 Wong, C. K. *et al.* Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin*
615 *Exp Immunol* **136**, 95-103, doi:10.1111/j.1365-2249.2004.02415.x (2004).
- 616 43 Yang, Y. *et al.* Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the
617 progression of COVID-19. *Journal of Allergy and Clinical Immunology* **146**, 119-127.e114,
618 doi:10.1016/j.jaci.2020.04.027 (2020).
- 619 44 Medford, A. R. & Millar, A. B. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and
620 acute respiratory distress syndrome (ARDS): paradox or paradigm? *Thorax* **61**, 621-626,
621 doi:10.1136/thx.2005.040204 (2006).
- 622 45 Ray, P. R. *et al.* A pharmacological interactome between COVID-19 patient samples and human sensory
623 neurons reveals potential drivers of neurogenic pulmonary dysfunction. *Brain, Behavior, and Immunity* **89**,
624 559-568, doi:<https://doi.org/10.1016/j.bbi.2020.05.078> (2020).
- 625 46 Xu, Z.-S. *et al.* Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and
626 fatal COVID-19 patients. *Signal Transduction and Targeted Therapy* **5**, 100, doi:10.1038/s41392-020-0211-1
627 (2020).
- 628 47 Chen, Y. G. (<https://ClinicalTrials.gov/show/NCT04275414>, 2020).
- 629 48 Blanco-Melo, D. *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell*
630 **181**, 1036-1045 e1039, doi:10.1016/j.cell.2020.04.026 (2020).
- 631 49 Peyneau, M. *et al.* Innate immune deficiencies in patients with COVID-19. *medRxiv*,
632 2021.2003.2029.21254560, doi:10.1101/2021.03.29.21254560 (2021).
- 633 50 Painter, M. M. *et al.* Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral
634 and cellular immune responses to SARS-CoV-2 mRNA vaccination. *Immunity*,
635 doi:<https://doi.org/10.1016/j.immuni.2021.08.001> (2021).
- 636 51 Loske, J. *et al.* Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2
637 infection in children. *Nature Biotechnology*, doi:10.1038/s41587-021-01037-9 (2021).
- 638 52 Capelle, C. M. *et al.* Standard Peripheral Blood Mononuclear Cell Cryopreservation Selectively Decreases
639 Detection of Nine Clinically Relevant T Cell Markers. *ImmunoHorizons* **5**, 711-720,
640 doi:10.4049/immunohorizons.2100049 (2021).
- 641 53 Robins, H. S. *et al.* Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.
642 *Blood* **114**, 4099-4107, doi:10.1182/blood-2009-04-217604 (2009).

643 **Figures:**




▲ HC Day1 ■ AS Day 1 ◆ Mild Day 1 ★ Hospitalized Day1 ▼ HC Day14 □ AS Day 21 ◇ Mild Day 21 ○ Hospitalized Day21 ● Severe ● Neg



645 **Figure 1. Cohort description and SARS-CoV-2 serological analysis of different**
646 **groups.**

647 **A**, Sample numbers, longitudinal sampling scheme and experimental overview of different COVID-
648 19 patient subgroups and household controls. AS, asymptomatic; HC, household controls.
649 **B**, Scatter dot plots of age from each individual of different participant groups.
650 **C, D, E, F**, SARS-CoV-2 spike-specific (**C**) or RBD-specific (**D**) or N-specific (**E**) or NTD-specific
651 (**F**) IgG titers at day 1 inclusion for each group, or day 21 post inclusion of different patient
652 subgroups or day 14 post inclusion of the household control group. The statistical test between
653 non-hospitalized groups was based on the signals (AU). Only the positive percentages, rather than
654 the signals of hospitalized samples were directly compared with that of other groups because
655 different lots of abs were used (for the positive threshold calculation, refer to **Methods**). Neg,
656 negative calibration sera from 2019 before the pandemic; Severe, positive sera from severe
657 patients of another cohort of the local hospital (see **Methods**).
658 **G, H**, Percentage inhibition by anti-SARS-CoV-2 Spike (**G**) or RBD (**H**) antibodies using a MSD
659 pseudo-neutralization assay. The sera were diluted 50x before the measurement.
660 **I, J**, Correlation between antibody titers and percentage inhibition of S (**I**) or RBD (**J**) antigens in all
661 the COVID-19 patient samples. Spearman correlation was used for the analysis.
662 Data represent individual values; Mean± standard deviation (S.D.); P-value in Figure **B-H** was
663 determined by the Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple
664 comparisons test. ns, not significant, * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$.
665



666

667 **Figure 2. Early-stage coordinated responses of CD4, CD8, mature DC and**
668 **Plasmablasts in mild COVID-19 patients.**

669

670 **A**, PCA plots of the samples from different patient groups at day 1 of inclusion and the house hold
671 controls at day 1 and day 14 post inclusion. The analysis was based on 484 immunological
672 features/subsets analyzed by multi-panel and multi-color flow cytometry.

673 **B**, Volcano plots of different immune features in patients with mild symptoms vs. household
674 controls at day1 of inclusion. The selected list of significantly increased or decreased subsets
675 ($p \leq 0.05$ and change fold ≥ 2) were marked in red or green, respectively. Tconv, FOXP3⁺CD4
676 conventional T cells.

677 **C, D, E, F, G**, Frequency of Ki67⁺ (**C**), CD38⁺ (**D**), HLA-DR⁺CD38⁺ (**E**), Tbet⁺Ki67⁺ (**F**),
678 EOMES⁺Ki67⁺ (**G**) among CD8 T cells from different groups at different time points. AS,
679 asymptomatic; HC, household controls; D1/D14/D21, day 1/day 14/day 21.

680 **H, K**, Representative flow cytometry plots of the expression of Tbet and Ki67 (**H**) or the expression
681 of CD38 and HLA-DR (**K**) on CD8 T cells from either household controls, mild or hospitalized
682 patients at day 1 of inclusion.

683 **I, J**, Frequency of Ki67⁺ (**I**) and Tbet⁺Ki67⁺ (**J**) among CD4 T cells.

684 **L**, Frequency of HLA-DR⁺CD38^{high} mature Dendritic cells (DC) among CD3⁻CD19⁻CD14⁻ cells.


685 **M**, Frequency of CD27^{high}CD38^{high} plasmablasts among CD3⁺CD19⁺IgD⁻ B cells.

686 **N, P**, Correlation between the frequency of CD38⁺ among CD8 at day 1 and anti-SARS-CoV-2N-
687 specific IgG titers at day 21 following inclusion from asymptomatic and mild patients (**N**) or from
688 hospitalized patients (**P**). Spearman correlation was used for the analysis.

689 **O, Q**, Correlation between the frequency of mature dendritic cells among CD3⁻CD19⁻CD14⁻ cells at
690 day 1 and anti-SARS-CoV-2N-specific IgG titers at day 21 following inclusion from asymptomatic
691 and mild patients (**O**) or from hospitalized patients (**Q**).

692 Data represent individual values; Mean \pm standard deviation (S.D.); P-value in Fig. **C-G, I-M** was
693 determined by the Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple
694 comparisons test. ns or unlabeled, not significant, * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$.

695



696

697

698

699

700 **A**, Volcano plot showing the comparison of the frequency of different immune subsets in mild

701 versus hospitalized patients at day 1. The selected list of significant increased or decreased

702 subsets ($p \leq 0.05$ and change fold ≥ 2) were marked in red or green, respectively. AS,

703 asymptomatic; HC, household controls; D1/D14/D21, day 1/day 14/day 21.

704 **B**, Proportions of HLA-DR⁺CD38⁻ non-classical monocytes (ncMono) among CD3⁺CD19⁻CD14⁻

705 cells.

706 **C**, **E**, **F**, Frequency of cells expressing CD86⁺CD80⁺ among ncMono (**C**) or pDC (**E**) or mDC (**F**)


707 among total DCs.

708 **D**, **G**, Representative flow-cytometry plots of the expression of HLA-DR and CD38 (**D**) or the

709 expression of CD11c and CD123 (**G**) from different groups.


710 **H**, Frequency of CD86⁺CD80⁺ cells among DCs.

711 **J, K**, Frequency of NK5 among CD3⁺ cells (**J**) or of KLRG1 among NK1 (**K**).
 712 **I**, Representative flow-cytometry plots of the expression of CD56 and CD16. Gating strategy to
 713 define six subsets of NK cells. Enlarged number from 1 to 6 represents various NK subsets.
 714 Data represent individual values; Mean± standard deviation (S.D.); P-value was determined by the
 715 Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple comparisons test. ns
 716 or unlabeled, not significant, *p<=0.05, **p<=0.01 and ***p<=0.001.
 717



718
 719
 720

721 **Figure 4. Early-stage transient cytokine responses in mild COVID-19 patients.**
722 **A**, Volcano plot showing the serological cytokine/chemokine responses in mild patients relative to
723 household controls (HC) at day 1 of inclusion. Significantly increased or decreased
724 cytokines/chemokines/growth factors ($p \leq 0.05$ and change fold ≥ 2) were marked in red or green,
725 respectively. The gray dot represents the analytes showing a significant change but displaying
726 values lower than the reported normal physiological levels even in control groups.
727 **B, C**, Scatter dot plots of serological levels of IP10 (**B**) and INF β (**C**) of different groups at day 1 or
728 day 14 or day 21 following inclusion. AS, asymptomatic; HC, household controls; D1/D14/D21, day
729 1/day 14/day 21.
730 **D, E**, Correlation between the frequency of mature DC and IP10 (**D**) or IFN β (**E**) at day 1 of
731 inclusion. R, Pearson correlation coefficient. Different groups were marked by different indicated
732 colours.
733 **F**, Volcano plot showing the responses of serological cytokines/chemokines of mild patients versus
734 hospitalized patients at day 1 of inclusion.
735 **G, H, I, J, K**, Scatter dot plots of IFN γ (**G**), Eotaxin1 (**H**), VEGF A (**I**), IL-6 (**J**) and IL-10 (**K**) of
736 different participant groups.
737 **L**, Frequency of FOXP3⁺ Treg cells among CD4 T cells.
738 Data represent individual values; Mean \pm standard deviation (S.D.); P-value was determined by the
739 Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple comparisons test. ns
740 or unlabeled, not significant, * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$. Gray shading indicates the
741 reported normal range for different cytokines/chemokines.
742



743

744 **Figure 5. Early-stage expansion of SARS-CoV-2-specific TCR clonotypes in**
745 **mild COVID-19 patients.**


746 **A**, Correlation between sample clonality and age of corresponding participants of the samples
747 ($n=144$) from all the groups. r , Spearman correlation coefficient.

748 **B**, Productive clonality (inverted normalized diversity index) of different groups. Different groups
749 were marked by different indicated colours. AS, asymptomatic; HC, household controls;
750 D1/D14/D21, day 1/day 14/day 21.

751 **C**, The usage frequency of the TCRbeta V06-07 gene among different groups.

752 **D, E**, Clonal breadth (**D**): Relative frequency of SARS-CoV-2-specific T cell clonotypes among
 753 unique productive rearrangements; Clonal Depth (**E**), expansion extent of SARS-CoV-2-specific T
 754 cell clonotypes.
 755 **F**, Clonal breadth of CD4 and CD8 SARS-CoV-2-specific TCR clonotypes among each individual
 756 participant from different groups. The values from every individual participant were linked through
 757 lines. The two D1 hospitalized patients were posited between Mild D1 and HC D14 (the gap
 758 between the dashed lines), but not labelled.
 759 **G, H**, Clonal breadth of CD4 (**G**) or CD8 (**H**) SARS-CoV-2-specific TCR clonotypes among
 760 different groups.
 761 **I, J**, Correlation between SARS-CoV-2-specific TCR clonal breadth and percentages of
 762 ICOS⁺Ki67⁺ among CD4 T cells (**I**) or among CD8 T cells (**J**) in asymptomatic and mild patients at
 763 day 1. Correlation coefficient was based on Spearman correlation. P-value was from the two-tailed
 764 test.
 765 Data represent individual values; Mean± standard deviation (S.D.); P-value from the Fig. **B-E, G-H**
 766 was determined by the Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple
 767 comparisons test. ns or unlabeled, not significant, *p<=0.05, **p<=0.01 and ***p<=0.001.

768 **Supplementary Figures:**




769
770

771 **Supplementary Figure 1. Whole-blood-count analysis of asymptomatic, mild**
 772 **and hospitalized patients at day 1 of inclusion.**

773 **A**, PCA plots of the samples from different patient groups at day 1 of inclusion based on 17 whole-
 774 blood-count parameters. AS, asymptomatic; HC, household controls; D1, day 1.
 775 **B, E, G**, the percentages of Lymphocytes (LYM, **B**), monocytes (Mon, **E**) and granulocytes (GRA,
 776 **G**).

777 **C**, CRP (C-reactive protein) levels from different patient groups at day 1 of inclusion.
 778 **D, F, H, I, J**, Number of white blood cells (WBC, **D**), monocytes (Mon, **F**), granulocytes (GRA, **H**),
 779 red blood cells (RBC, **I**) and platelets (PLT, **J**) per ul (mm³).
 780 **K**, the hematocrit levels (%) from different patients groups at day 1 of inclusion.
 781 Data represent individual values; Mean± standard deviation (S.D.); P-value was determined by the
 782 Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple comparisons test. ns
 783 or unlabeled, not significant, *p<=0.05, **p<=0.01 and ***p<=0.001. Gray shading indicates the
 784 reported normal range for those different laboratory parameters.
 785
 786




787

788 **Supplementary Figure 2. General gating strategy to identify different immune**
 789 **subsets analysed in our study.**

790 **A**, Lymphocyte gating strategy (not including B cells). Treg, FOXP3⁺CD4 T cells; Tconv, FOXP3⁻
 791 CD4 T cells; NK, natural killer cells.

792 **B**, Gating strategy to identify B cells, (non-)class-switched memory B cells, naïve B cells T cells,
 793 monocytes, DC, mDC, pDC, mature DC and plasmablasts. ncMono, non-classical monocytes; DC,
 794 Dendritic cells.

795 Due to limited space, the functional markers or their combinations among each subset were not
 796 displayed here. It is also worthy to note that we used three different panels to perform a deep
 797 immunophenotyping analysis by flow cytometry. For some markers, different fluorochromes were
 798 used in different panels.
 799
 800




801

802 **Supplementary Figure 3. Comprehensive comparison of immune responses**
 803 **between asymptomatic patients and household controls.**

804 **A, B**, Volcano plots showing the immune responses in asymptomatic patients at day 1 (**A**) or day
 805 21 (**B**) following inclusion. Significant increased or decreased subsets ($p \leq 0.05$ and change fold
 806 ≥ 2) were marked in red or green, respectively. The gray dot represents the subset not showing a
 807 significant change after applying the Dunn's multiple comparison test.

808 **C**, Frequency of ICOS⁺ cells among CD8 T cells of different participant groups. AS, asymptomatic;
 809 HC, household controls; D1/D14/D21, day 1/day 14/day 21.

810 Data represent individual values; Mean \pm standard deviation (S.D.); P-value was determined by the
 811 Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple comparisons test. ns
 812 or unlabeled, not significant, * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$.
 813



828 **Supplementary Figure 5. Comprehensive peripheral immune profiling of mild**
829 **patients at day 21 following inclusion.**


830 **A**, Volcano plot showing responses of different immune subsets in mild patients at day 21 following
831 inclusion relative to household controls (HC) at day 14 following inclusion. Significant increased or
832 decreased subsets ($p \leq 0.05$ and change fold ≥ 2) were marked in red or green, respectively. The
833 gray dot represents the subset not showing a significant change after applying the Dunn's multiple
834 comparison test.

835 **B**, GZMB MFI among CD8 T cells from different groups. AS, asymptomatic; HC, household
836 controls; D1/D14/D21, day 1/day 14/day 21.

837 **C**, Frequency of CD45RO⁺Ki67⁺ among CD8 T cells from different groups.

838 **D, E, F, G**, Frequency of CD57⁺ (**D**), GZMB⁺ (**E**), CD45RO⁺CD57⁺ (**F**) or CD57⁺GZMB⁺ (**G**) among
839 CD4 Tconv cells from different groups.

840 Data represent individual values; Mean \pm standard deviation (S.D.); P-value was determined by the
841 Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple comparisons test. ns
842 or unlabeled, not significant, * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$.
843



844

845 **Supplementary Figure 6. Extended analysis of early-stage immune features**
846 **characterizing mild patents from hospitalized ones.**

847

848 **A, B**, Frequency of cells expressing PD-L1 (**A**) or CD13 (**B**) among ncMono from different
849 participant groups. AS, asymptomatic; HC, household controls; D1/D14/D21, day 1/day 14/day 21.

850 **C**, Frequency of CD13⁺ among HLA-DR⁺CD38⁺ DCs.

851 **D, E**, Frequency of CD27⁺ICOS⁺ among CD4 cells (**D**) or ICOS MFI (**E**) among CD8 T cells.


852 **F, G**, Frequency of KLRG1⁺ cells among NK3 (**F**) or frequency of PD-1⁺ cells among NK5 (**G**).

853 **H, I**, CD86 MFI (**H**) or the frequency of PD-L1⁺ cells (**I**) among class-switched memory B cells.

854 **J, K**, Frequency of CD40L⁺ cells (**J**) or frequency of PD-1⁺GZMB⁺ cells (**K**) among CD8 T cells.

855 Data represent individual values; Mean± standard deviation (S.D.); P-value was determined by the
856 Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple comparisons test. ns
857 or unlabeled, not significant, *p<=0.05, **p<=0.01 and ***p<=0.001.

858



859

860 **Supplementary Figure 7. Extended comparison of serological**
 861 **cytokine/chemokine responses between different patient groups at day 1 or**
 862 **day 21 following inclusion.**

863 **A**, Volcano plot showing cytokine/chemokine responses of mild patients at day 21 versus
 864 household controls (HC) at day 14 following inclusion.

865 **B**, Volcano plot showing cytokine/chemokine responses of asymptomatic patients versus
 866 household controls (HC) at day 1 of inclusion.

867 **C**, Volcano plot showing cytokine/chemokine responses of asymptomatic (AS) patients at day 21
 868 versus household controls (HC) at day 14 following inclusion.

869 **D**, Volcano plot showing cytokine/chemokine responses of mild patients versus hospitalized
870 patients at day 21 of inclusion. The gray dot represents the analytes showing a significant change
871 but displaying values lower than the reported normal physiological levels even in control groups.
872 **E**, Scatter dot plots of serological levels of IL-5 of different participant groups in the cohort. Gray
873 shading indicates the reported normal range for IL-5.
874 AS, asymptomatic; HC, household controls; D1/D14/D21, day 1/day 14/day 21.
875 Data represent individual values; Mean± standard deviation (S.D.); P-value was determined by the
876 Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple comparisons test. ns
877 or unlabeled, not significant, *p<=0.05, **p<=0.01 and ***p<=0.001.

878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916

917 **Materials and Methods:**

918

919 **Cohort design**

920 Predi-COVID is a prospective longitudinal cohort study composed of individuals older than 18
921 years of age with a positive PCR test for SARS-CoV-2 in Luxembourg. Blood samples were
922 collected by a nurse at the latest 3 days post clinical PCR diagnosis (baseline, as day 1) at home
923 for asymptomatic and mild participants. For hospitalized patients, except for two of them (sampled
924 5 or 6 days post hospital arrival), the remaining 13 patients were all sampled at the latest 3 days
925 after hospitalization. A follow-up visit was organized 3 weeks (day 21) later.

926

927 The Predi-COVID-H sub-study is a prospective longitudinal cohort study composed of household
928 members of a Predi-COVID participant as controls. Biological samples were collected at the same
929 time as for the Predi-COVID participant sharing the house (baseline, as day 1) and 2 weeks later,
930 at day 14. More details on the study design have been described ¹⁶.

931 **Blood sampling and PBMC isolation**

932 Samples were collected from confirmed SARS-COV-2 positive patients and household controls by
933 trained nurses from the LIH-CIEC. Blood samples were collected in CAT, K₂EDTA and CPT (all
934 from BD, Erembodegem, Belgium) by the standard phlebotomy procedure. Blood samples were
935 transported daily to centralized processing laboratory (IBBL) at ambient temperature.

936

937 CAT tubes were centrifuged for 10 min at 2000 x g room temperature (RT). Serum upper layer was
938 sterile aliquoted and stored at -80 °C. Prior to centrifugation, 200 µl from the K₂EDTA was
939 transferred into 0.5 ml microcentrifuge tube for complete blood count (CBC) on ABX Micros
940 CRP200 (Horiba, Japan). The K₂EDTA tube was centrifuged for 20 min at 2000 x g, 4 °C. Plasma
941 upper layer and buffy-coat were aliquoted and stored at -80 °C. The CPT tubes were centrifuged
942 for 20 min at 1800 x g, RT. The collected PBMCs were washed twice in PBS and counted using a
943 Cellometer (Nexcelom, UK). Fresh PBMCs were partly used for direct flow cytometry and partly
944 cryopreserved in CryoStor CS10 (Biolife solutions, USA) by controlled-rate freezing using Mr.
945 Forsty (Nalgene, USA), followed by a long-term storage in liquid nitrogen.

946 **Flow cytometry**

947 For each panel staining, 1x10⁶ isolated fresh PBMCs, rather than frozen PBMCs, were used since
948 cryopreservation affects several relevant markers⁵². The cells were resuspended in 50 µl of
949 Brilliant stain buffer (BD, 563794) containing 2.5 µl of Fc blocking antibodies (BD, 564765) and
950 incubated for 15 min. The suspension was then mixed with 50 µl of the respective 2x concentrated
951 mastermix for the surface staining. The staining concentration and fluorochromes of the different

952 markers are specified in **Supplementary Table 2**. After 30 min of incubation in the dark at 4 °C,
953 the cells were washed three times with FCM buffer (flow cytometry [FCM] staining buffer, Ca²⁺-
954 and Mg²⁺-free PBS + 2% heat-inactivated FBS) (5 min, 300 x g). Following the final washing step,
955 the stained PBMCs were fixed in 200 ul of 4% PFA (ThermoFisher Scientific, 28906) and
956 incubated at RT for 30 min in the dark. After the PFA fixation, the PBMCs were washed once in
957 FCM buffer (5 min, 400 x g) and resuspended in 200 ul fixation buffer from the True-Nuclear
958 Transcription Factor Buffer Set (Biolegend, 424401). After 1 h of incubation in the dark at RT, the
959 cells were centrifuged down (5 min, 400 x g) and resuspended in 200 ul FCM buffer and left at 4 °C
960 overnight.

961 In the next morning the cells were resuspended in permeabilisation buffer (Biolegend, 424401)
962 containing 2.5 ul of Fc blocking antibodies (BD, 564765) and incubated for 15 min at RT. After the
963 intracellular blocking step, the cells were resuspended in 100 ul permeabilisation buffer containing
964 the antibodies for the intracellular staining (**Supplementary Table 2**). After 30 min of incubation at
965 RT in the dark, the cells were washed 3 times with permeabilisation buffer (5 min, 400 x g) and
966 resuspended in 100 ul FCM buffer to proceed to the acquisition on a BD LSRFortessa™ analyzer.
967 To ensure a consistent acquisition of all the markers over the whole duration of the study, the
968 application settings of the instrument were saved during the first acquisition and applied to all the
969 following samples of the cohort. The data was analyzed using FlowJo v10.5.6.

970

971 **Determination of cytokine and chemokine levels by MSD assay**

972 24 cytokines, chemokines or growth factors (eotaxin-1, G-CSF, GM-CSF, IFN-α2a, IFN-β, IFN-γ,
973 IL-1α, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL12p70, IL-13, IL-33, IP10, MCP-1, MIP-1α, TARC, TNF-α,
974 TNF-β, TSLP, VEGFA) were measured in patient sera using a multiplex assay (U-Plex Biomarker
975 Group 1 (hu) assays from MSD Kit catalog Number K15067L-1). The samples were undiluted. The
976 assay was performed according to the manufacturer's instructions. Data were recorded and
977 analyzed on a MESO QuickPlex SQ 120 instrument.

978

979 **Serological detection of IgG against SARS-CoV-2 by MSD assay**

980 V-Plex COVID-19 Coronavirus Panel1 serology kits from MSD (reference K15362U) were used to
981 detect the presence of IgG antibodies to SARS-CoV-2-Spike (S), SARS-CoV-2 Nucleocapsid (N),
982 SARS-CoV-2-S NTD (NTD) and SARS-CoV-2-S RBD (RBD) in diluted sera (1/500) according to
983 the manufacturer's instructions. The plate was read on an MSD instrument, which measures the
984 light emitted from the MSD SULFO-TAG. To determine the cutoff values for positivity for SARS-
985 CoV-2, we measured 35 patients in another cohort from Central Hospital of Luxembourg (PCR
986 positive and >15 days symptom onset) and negative sera before the pandemic from 2019 stored in

987 Luxembourg National Laboratory (LNS). The values of IgG for severe ones from that cohort as
988 defined positive controls have already been displayed in Fig. 1. Of note, the hospitalized samples
989 (both at day 1 and day 21 of inclusion) in this cohort were measured using lots of plates different
990 from the other groups and the corresponding positive thresholds of those plates were calculated
991 accordingly. To guarantee the comparability of positive percentages between the two batches, the
992 choice of the cutoffs aimed for a similar sensitivity and specificity between the two batches of
993 plates (the AUC analysis was done by GraphPad Prism 9.0).

994

995 **Determination of neutralization antibody capacity by MSD assay**

996 Multiplex assays for the detection of neutralizing antibodies against SARS-CoV-2 (SARS-CoV-2-
997 Spike and SARS-CoV-2 S RBD) were done on patient sera using the MSD COVID-19 ACE2
998 Neutralization Kits from MSD (Panel 1 reference K15375U) according to the manufacturer's
999 instructions. The samples were diluted 50 times for the neutralization assay. Data were recorded
1000 on a MESO QuickPlex SQ 120 instrument, which measures the light emitted from the MSD
1001 SULFO-TAG. Results were reported as percent inhibition calculated using the equation below. %
1002 Inhibition was calculated using the following equation: $(1 - \text{Average Sample ECL Signal} / \text{Average ECL signal of calibrator}) * 100$.

1004

1005 **TCR repertoire analysis**

1006

1007 Immunosequencing of the CDR3 regions of human TCR β chains was performed using the
1008 ImmunoSEQ[®] Assay (Adaptive Biotechnologies, Seattle, WA). Extracted genomic DNA from ~5e6
1009 cryopreserved PBMCs was amplified in a bias-controlled multiplex PCR, followed by high-
1010 throughput sequencing. Sequences were collapsed and filtered in order to identify and quantitate
1011 the absolute abundance of each unique TCR β CDR3 region for further analysis as previously
1012 described⁵³.

1013

1014 Clonality was defined as 1- normalized Shannon's Entropy and was calculated on productive
1015 rearrangements. Clonality values approaching 0 indicate a very even distribution of frequencies,
1016 whereas values approaching 1 indicate an increasingly asymmetric distribution in which a few
1017 clones are present at high frequencies. Clonal breadth and depth of SARS-CoV2-associated TCR β
1018 sequences were calculated as previously described²⁸, using a set of sequences described
1019 elsewhere²⁹. Briefly, breadth is calculated as the proportion of unique annotated SARS-CoV-2
1020 specific rearrangements out of the total number of unique productive rearrangements, while depth
1021 accounts for the extent of the expansion of those clonal lineages in the repertoire.

1022

1023 **Ethics statements**

1024

1025 All collections were performed with approval from relevant ethic organizations. Informed consent
1026 was obtained from each participant prior to collection. The blood sampling was performed by
1027 nurses from Clinical and Epidemiological Investigation Centre (CIEC) of LIH.

1028 **Statistical analysis**

1029

1030 Both PCA and volcano plots were visualized using GraphPad Prism 9.0. Correlation analysis was
1031 based on either Spearman or Pearson correlation as indicated in the corresponding figures. We
1032 only displayed the top-ranked highly correlated results if the correlation coefficient was ranked in
1033 the top positions among 484 correlations, calculated between antibody levels, cytokines or TCR
1034 breadth and any of the 484 subsets. The corresponding P-values from correlation analysis were
1035 based on a two-tailed analysis using GraphPad Prism 9.0. P-value from each scatter dot plots was
1036 determined by the Kruskal-Wallis (nonparametric) test and corrected using the Dunn's multiple
1037 comparisons test from GraphPad Prism 9.0. In addition to each individual value, data from each
1038 group were presented as mean± standard deviation (S.D.). ns or unlabeled, not significant,
1039 * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$.

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066 **Supplementary Tables**

1067 **Supplementary Table 1. Demographics of our longitudinal COVID-19 cohort.**

1068

Clinical characteristics of the cohort	All patients, D1	Asymptomatic, D1	Mild, D1	Hospitalized, D1	Household controls, D1	All patients, D21	Asymptomatic, D21	Mild, D21	Household Controls, D14
median (IQR)									
Age (years)	44 (30-53)	44 (24.5-55.5)	38 (28.5-48)	57 (49-61)	33.5 (26-40.75)	40.5 (30.8-48.5)	44 (29-53)	40 (31-48)	33.5 (27-42.25)
BMI	25.7 (23.5-28.6)	24.8 (22.9-26.6)	25.8 (23.5-29.4)	26.64 (24.9-29.1)		25.9 (23.9-27.9)	24.8 (22.3-26.1)	26.3 (24.4-28.7)	
concerned n (percentage among the given category)									
Male (%)	54 (63.5%)	9 (69.2%)	39 (63.9%)	8 (57.1%)	7 (30.4%)	33 (66%)	8 (72.7%)	25 (64.1%)	7 (35%)
Smoking (%)	14 (18.7%)	3 (23.1%)	11 (18.1%)			9 (18%)	2 (18.2%)	7 (18%)	
Former smoker (%)	16 (21.4%)	2 (15.4%)	14 (23%)			12 (24%)	2 (18.2%)	10 (25.7%)	
Whole Blood Count parameters: median (IQR)									
WBC, white blood cell count (10E3/uL)	5.25 (3.9-7.625)	5.3 (4.4-6.1)	4.6 (3.5-5.7)	9.6 (8.85-11.05)					
#Lymphocyte, LYM (10E3/uL)	1.65 (1.2-2.1)	1.8 (1.4-2.1)	1.6 (1.2-2.1)	1.6 (1-2.1)					
%Lymphocyte, LYM (%)	34.05 (25.575-40.75)	33 (29.8-37.7)	36.9 (31-43.9)	16.8 (10.95-21.3)					
#Monocyte, MON (10E3/uL)	0.3 (0.2-0.6)	0.3 (0.28-0.43)	0.2 (0.2-0.4)	1.2 (0.7-2)					
%Monocyte, MON (%)	7.3 (6.4-9.65)	7.15 (6.5-7.9)	6.9 (5.8-8.5)	12.8 (9.7-17.1)					
#Granulocyte, GRA (10E3/uL)	3.05 (2.175-4.6)	3.35 (2.5-3.8)	2.6 (1.8-3.8)	7.2 (6.25-7.55)					
%Granulocyte, GRA (%)	58.1 (50.9-65.2)	59.7 (52.1-63)	54.7 (48.7-62.7)	67.8 (64.15-77.05)					
Red Blood Cell, RBC (10E6/uL)	5.265 (4.865-5.7125)	5.41 (5.0-5.7)	5.31 (5.1-5.9)	4.73 (4.335-4.945)					
Hemoglobin, HGB (g/dl)	15.5 (14.1-17.025)	15.6 (15.1-17.4)	15.8 (14.7-17)	13.9 (13.05-14.85)					

Hematocrit, HCT (%)	48.25 (44.05-52.65)	49.1 (46.9-54.4)	48.8 (45.6-52.8)	42.9 (39.5-45.7)					
Platelet, PLT (10E3/uL)	175 (144-212)	179.5 (154.8-209.3)	167 (130-199)	235 (163-286.5)					
Mean Cell Volume, MCV (um3)	92 (89-94)	92.5 (89.8-95)	92 (89-94)	91 (90-93)					
Mean Cell Hemoglobin, MCH (pg)	29.35 (28.5-30.85)	29.35 (28.5-30.3)	28.9 (28.5-30.7)	30.4 (29.9-31)					
Mean Cell Hemoglobin Concentration, MCHC (g/dL)	32.1 (31.6-32.6)	31.9 (31.8-32.4)	32 (31.4-32.4)	33.3 (33-33.5)					
Red Cell Distribution Width, RDW (%)	14.35 (14-14.7)	14.45 (14.1-14.6)	14.4 (14.1-14.8)	14.1 (13.95-14.55)					
Mean Platelet Volume, MPV (um3)	8.4 (8-8.8)	8.35 (8.1-9.0)	8.4 (8-8.7)	8.3 (8-8.6)					
C-reactive protein, CRP (mg/L)	0.65 (0-10.075)	0 (0-0.03)	0.4 (0-1.6)	38 (18.4-58)					
Comorbidity: concerned n (the percentage among the given category)^s									
Hypertension	8(10.7%)	2(15.4%)	6(9.9%)			6(12%)	1(9.1%)	5 (12.9%)	NA*
Chronic heart disease, including congenital heart disease (except hypertension)	5(6.7%)	1(7.7%)	4(6.6%)			2 (4%)	1(9.1%)	1(2.6%)	NA
Chronic lung disease (except asthma)	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%)	0 (0%)	NA
Asthma (clinical diagnosis made)	3 (4%)	0 (0%)	3 (5%)			0 (0%)	0 (0%)	0 (0%)	NA
Chronic kidney disease	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%)	0 (0%)	NA
Renal failure requiring dialysis	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%)	0 (0%)	NA
Moderate or severe liver disease	1(1.4%)	0 (0%)	1 (1.7%)			1 (2%)	0 (0%)	1(2.6%)	NA
Mild liver disease	1(1.4%)	1 (7.7%)	0 (0%)			1 (2%)	1 (9.1%)	0 (0%)	NA
Chronic neurological disorder	1(1.4%)	0 (0%)	1 (1.7%)			0 (0%)	0 (0%)	0 (0%)	NA
Cancer	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%)	0 (0%)	NA
Chronic hematologic disease	3 (4%)	0 (0%)	3 (5%)			1 (2%)	0 (0%)	1(2.6%)	NA
HIV / AIDS	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%)	0 (0%)	NA
Obesity (clinical diagnosis made)	4(5.4%)	0 (0%)	4 (6.6%)			4 (8%)	0 (0%)	4(10.3%)	NA
Diabetes with associated complications	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%)	0 (0%)	NA
Uncomplicated diabetes	5 (6.7%)	0 (0%)	5 (8.2%)			2 (4%)	0 (0%)	2(5.2%)	NA
Rheumatologic disease	1 (1.4%)	0 (0%)	1 (1.7%)			1 (2%)	0 (0%)	1(2.6%)	NA

Malnutrition	1(1.4%)	0 (0%)	1 (1.7%)			1 (2%)	0 (0%)	1(2.6%)	NA
Chronic obstructive pulmonary disease (COPD)	1(1.4%)	0 (0%)	1 (1.7%)			0 (0%)	0 (0%)	0 (0%)	NA
Other notable diseases or risk factors	12(16%)	1 (7.7%)	11(18.1%)			8 (16%)	0 (0%)	8(20.6%)	NA

1069

1070 §, the total number of patients only include asymptomatic and mild patients, but not hospitalized
1071 patients.

1072 *, NA or empty, no information available.

1073 IQR: 25% percentile-75% percentile.

1074 n, the number of participants in the given category.

1075 **Supplementary Table 2. List of antibodies used in this study.**

Marker and Fluorochrome	Supplier	Reference	Dilution
Fc Block	BD	564765	2.5ul/1M cells
CD4 BUV395	BD	563550	1 :200
CD8 BUV496	BD	612942	1 :200
CD3 BUV737	BD	741822	1 :200
CD56 BV510	BD	740171	1 :50
Tim3 BV786	BD	742857	1 :50
CD57 FITC	BD	561906	1 :100
CD16 BB700	BD	746199	1 :50
GZMB PE (intracellular) [§]	BD	561142	1 :20
CD45RO PE-CF594	BD	562299	1 :50
CD38 BV510*	BD	563251	1 :25
CXCR5 BV711	BD	740737	1 :200
HLA-DR BV786	BD	564041	1 :50
Ki67 AF588 (intracellular)	BD	561165	1 :50
CD27 BB700	BD	566449	1 :50
CD40L PE-Cy5	BD	555701	1 :50
CD86 BUV395	BD	740305	1 :25
IgD BUV 496	BD	741170	1 :200
CD14 BUV737	BD	612763	1 :100
CD123 BV421	BD	563362	1 :50
CD3 BV510	BD	564713	1 :100
CD40 BV605	BD	740410	1 :200
CD13 BV711	BD	740772	1 :25
PD-L1 BB515	BD	564554	1 :50
CD19 BB700	BD	566411	1 :200
CD38 PE	BD	560981	1 :25
CD11c PE-CF594	BD	562393	1 :50
CD80 PE-CY7	BD	561135	1 :25
CD27 APC	BD	561786	1 :50
ICOS (CD278) BV605	BioLegend	313538	1 :100

KLRG1 PE-Cy7	BioLegend	368614	1 :50
FOXP3 APC (intracellular)	BioLegend	320114	1 :20
CCR7 (CD197) BV421	BioLegend	353208	1 :50
CD45RA BV421	BioLegend	304130	1 :50
PD-1 (CD279) BV605	BioLegend	329924	1 :50
CD127 BV711	BioLegend	351328	1 :100
T-bet PE (intracellular)	BioLegend	644810	1 :50
CD194 APC	BioLegend	359408	1 :100
Eomes PE-Cy7 (intracellular)	ThermoFischer Scientific	25-4877-42	1 :20
True-Nuclear kit	BioLegend	424401	
Ultracomp Comp Beads	ThermoFischer Scientific	01-2222-42	

1076

1077 §, intracellular, indicating an intracellular staining protocol was applied; otherwise, cell surface
1078 staining.

1079 *, different fluorochromes were used for some markers among different panels.

1080